BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
November 01 2021 - 7:00AM
BioNTech to Present New Clinical Data from First-in-Class CAR-T
Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
MAINZ, Germany, November 1, 2021 (GLOBE
NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”), a next generation immunotherapy company pioneering novel
therapies for cancer and infectious diseases, today announced that
new clinical data from the first-in-human Phase 1/2 trial
evaluating the Company’s novel CAR-T cell therapy candidate,
BNT211, will be presented in an oral presentation. The presentation
is scheduled for the late-breaking abstract poster session at the
36th Annual Meeting of the Society for Immunotherapy of Cancer
(SITC), being held both in person and virtually from November 10 -
14, 2021.
“Our goal is to leverage our understanding of
immunology and tumor biology together with our advanced
technologies to provide cancer patients with novel treatments,”
said Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at
BioNTech. “Claudin-6 is a new target that we believe is
well-suited for CAR-T therapy and presents a differentiated avenue
for the treatment of solid tumors. We appreciate the opportunity to
present initial data from our first-in-human study of the CAR-T
product candidate to leading immuno-oncology experts in this
prestigious late-breaking forum, which further underline the
potential of our technology.”
BNT211 is an autologous CAR-T cell therapy
targeting the oncofetal antigen Claudin 6 (CLDN6) and the first
CAR-T product candidate in the Company’s clinical development.
BNT211 is currently being investigated as a monotherapy and in
combination with a CLDN6-encoding mRNA-based vaccine (CARVac) in a
first-in-human Phase 1/2 clinical trial (NCT04503278) to evaluate
safety and preliminary efficacy in patients with CLDN6-positive
relapsed or refractory advanced solid tumors.
Poster Details:
Program: BNT211Poster Title: A
phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T
cells and vaccine-mediated in vivo expansion in patients with
CLDN6-positive advanced solid tumorsAbstract Number:
958Presenter: Prof. Andreas Mackensen, M.D., University
Hospital Erlangen, GermanyDate & Time: Friday, November
12, 2021; 12.25 – 12.40 pm ET
About BioNTechBiopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
checkpoint immuno-modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, please visit
www.BioNTech.de
Investor RelationsSylke Maas, Ph.D. VP
Investor Relations & Strategy Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de
Media RelationsJasmina AlatovicDirector
Global External Communications Tel: +49 (0)6131 9084 1513 or +49
(0)151 1978 1385 E-mail: Media@biontech.de
Biontech (LSE:0A3M)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biontech (LSE:0A3M)
Historical Stock Chart
From Apr 2023 to Apr 2024